Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.89
-1.10 (-4.08%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Mineralys Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -154.65 | -177.81 | -71.9 | -29.8 | -19.41 | |
| Depreciation & Amortization | 0.06 | 0.04 | - | - | - | |
| Loss (Gain) From Sale of Investments | -9.88 | -9.41 | -6.87 | -0.65 | - | |
| Stock-Based Compensation | 19.32 | 11.34 | 5.06 | 0.46 | 0.08 | |
| Other Operating Activities | - | - | - | - | 0.68 | |
| Change in Accounts Payable | 0.43 | 4.16 | 2.42 | 3.01 | 4.47 | |
| Change in Other Net Operating Assets | 2.3 | 5.36 | -9.89 | -2.24 | -0.39 | |
| Operating Cash Flow | -142.42 | -166.31 | -81.17 | -29.22 | -14.56 | |
| Capital Expenditures | -0.02 | -0.1 | - | - | - | |
| Investment in Securities | -389.74 | 115.06 | -160.47 | -21.76 | - | |
| Investing Cash Flow | -389.75 | 114.96 | -160.47 | -21.76 | - | |
| Issuance of Common Stock | 591.39 | 116.58 | 203.25 | - | - | |
| Other Financing Activities | -0.39 | -0.44 | - | -1.63 | - | |
| Financing Cash Flow | 591 | 116.14 | 203.25 | 128.02 | 23.81 | |
| Net Cash Flow | 58.83 | 64.79 | -38.4 | 77.04 | 9.25 | |
| Free Cash Flow | -142.43 | -166.41 | -81.17 | -29.22 | -14.56 | |
| Free Cash Flow Per Share | -2.10 | -3.43 | -2.24 | -5.66 | -2.92 | |
| Levered Free Cash Flow | -84.38 | -99.43 | -55.27 | -18.4 | -7.62 | |
| Unlevered Free Cash Flow | -84.38 | -99.43 | -55.27 | -18.4 | -7.61 | |
| Change in Working Capital | 2.73 | 9.52 | -7.47 | 0.77 | 4.09 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.